Sarepta Therapeutics to Showcase Data from its Gene Therapy and RNA Platforms at World Muscle Society 2021 Virtual Congress
14 September 2021 - 10:30PM
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision
genetic medicine for rare diseases, will present at the World
Muscle Society 2021 Virtual Congress (WMS 2021), taking place Sept.
20-24, 2021. This year’s presentations at WMS 2021 highlight
scientific leadership and innovation from across Sarepta’s deep,
multi-platform portfolio and reflect the Company’s continued
commitment advancing life-changing therapies to those with rare
genetic diseases.
Presented research
will include data from the Company’s gene therapy and RNA
platforms, in addition to new research into the prevalence of
pre-existing antibodies to the AAVrh74 vector, which is used in
several of Sarepta’s gene transfer therapy programs.
All posters are available on-demand throughout the Congress
beginning on Monday, Sept. 20, 2021 at 7:00 am E.T. The full WMS
2021 program is available at
https://www.wms2021.com/page/programme.
Poster Presentations
Poster # |
Title |
EP.096 |
Micro-dystrophin gene therapy delivery and therapeutic plasma
exchange in nonhuman primates |
EP.139 |
Phase 1/2a trial of SRP-9001 in patients with Duchenne muscular
dystrophy: 3-year safety and functional outcomes
(SRP-9001-101) |
EP.149 |
Delay in Duchenne muscular dystrophy progression with eteplirsen:
Longer time to loss of ambulation versus standard of care |
EP.150 |
Casimersen in patients with Duchenne muscular dystrophy
amenable to exon 45 skipping: Interim results from the Phase 3
ESSENCE trial |
EP.151 |
Evaluation of total binding antibodies against rAAVrh74 in patients
with Duchenne muscular dystrophy |
EP.152 |
ENDEAVOR: A gene delivery study to evaluate the safety of and
expression from SRP-9001 in Duchenne muscular dystrophy
(SRP-9001-103) |
EP.185 |
Safety, β-sarcoglycan expression, and functional outcomes
from systemic gene transfer of rAAVrh74.MHCK7.SGCB in
limb girdle muscular dystrophy type 2E/R4 |
EP.254 |
A Phase 2 clinical trial evaluating the safety and efficacy of
SRP-9001 for treating patients with Duchenne muscular
dystrophy (SRP-9001-102) |
LBP.22 |
Safety, tolerability, and pharmacokinetics of eteplirsen in
patients 6-48 months old with Duchenne muscular dystrophy amenable
to exon 51 skipping |
Presentations will be archived on the events and
presentations page in the Investor Relations section of
www.sarepta.com for one year following their presentation at WMS
2021.
About Sarepta
TherapeuticsSarepta is on an urgent mission: engineer
precision genetic medicine for rare diseases that devastate lives
and cut futures short. We hold leadership positions in Duchenne
muscular dystrophy (DMD) and limb-girdle muscular dystrophies
(LGMDs), and we currently have more than 40 programs in various
stages of development. Our vast pipeline is driven by our
multi-platform Precision Genetic Medicine Engine in gene therapy,
RNA and gene editing. For more information, please
visit www.sarepta.com or follow us on Twitter, LinkedIn,
Instagram and Facebook.
Internet
Posting of InformationWe routinely post information that
may be important to investors in the 'For Investors' section of our
website at www.sarepta.com. We encourage investors and
potential investors to consult our website regularly for important
information about us.
Source: Sarepta Therapeutics, Inc.
Investor Contact: Ian Estepan,
617-274-4052iestepan@sarepta.com
Media Contact: Tracy Sorrentino,
617-301-8566tsorrentino@sarepta.com
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Apr 2024 to May 2024
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From May 2023 to May 2024